Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute
Gernot G U Rohde1, Armin Koch, Tobias Welte
1Department of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands. g.rohde@mumc.nl.
Background:
Antibiotic-resistant strains of pathogenic bacteria are increasingly prevalent in hospitals and the community. Acute exacerbations of COPD (AE-COPD) often result in administration of antibiotics although more than half of exacerbations are associated with detection of respiratory viruses and potentially pathogenic bacteria can only be detected in 20-30% of cases. There is a paucity of placebo-controlled clinical trials and up to today no single study has been powered sufficiently to prove the efficacy of antibiotic treatment in AE-COPD. Most studies so far did not include current standards of care comprising administration of systemic corticosteroids.
Methods/Design:
A total of 980 patients with moderate acute exacerbations will be included in 22 German centers (hospitals and private practices). Patients will receive a standardized treatment for exacerbation including systemic corticosteroids, inhaled bronchodilators and supplementary oxygen if needed and will be randomized to additional treatment with placebo or antibiotic (oral sultamicillin) for five days.The primary endpoint is clinical failure defined by need for additional antibiotic treatment until day 30. Secondary endpoints will assure that management of AE-COPD without antibiotics does not result either in increased occurrence of relapse, new exacerbations, prolonged recovery, or unwanted long-term consequences.
Discussion:
ABACOPD will be the first sufficiently powered double-blind placebo-controlled study in the field to systematically assess the question whether antibiotics, known to increase antibiotic resistance, are really needed in a well-defined patient cohort receiving state-of-the art treatment in all other aspects.
Trial Registration Number:
ClinicalTrials.gov: NCT01892488.
Insights
This study investigates whether antibiotics are necessary for acute exacerbations of COPD (AE-COPD) when patients receive standard care. Results will inform antibiotic stewardship and treatment guidelines for AE-COPD.
Area of Science:
- Respiratory Medicine
- Infectious Diseases
- Clinical Pharmacology
Background:
- Rising antibiotic resistance necessitates re-evaluating antibiotic use in common infections.
- Acute exacerbations of COPD (AE-COPD) are frequently treated with antibiotics, despite viral causes in over 50% of cases.
- Current evidence for antibiotic efficacy in AE-COPD is limited, with few adequately powered, placebo-controlled trials, and most exclude standard corticosteroid treatment.
Purpose of the Study:
- To determine if antibiotics are required for treating acute exacerbations of COPD (AE-COPD) in patients receiving state-of-the-art care.
- To assess the impact of antibiotic treatment versus placebo on clinical failure rates in AE-COPD.
- To evaluate the safety and efficacy of withholding antibiotics in AE-COPD regarding relapse, new exacerbations, and recovery.
Main Methods:
- A large-scale, double-blind, placebo-controlled trial (ABACOPD) involving 980 patients across 22 German centers.
- Standardized AE-COPD treatment including systemic corticosteroids, bronchodilators, and oxygen as needed, with randomization to 5-day oral sultamicillin or placebo.
- Primary endpoint: clinical failure (need for additional antibiotics by day 30). Secondary endpoints: relapse, new exacerbations, recovery time, and long-term consequences.
Main Results:
- This section is not available in the provided abstract.
Conclusions:
- The ABACOPD study is the first adequately powered, double-blind, placebo-controlled trial to rigorously assess antibiotic necessity in AE-COPD.
- Findings will clarify the role of antibiotics in AE-COPD management within the context of modern, comprehensive treatment protocols.
- The study aims to guide antibiotic stewardship and reduce the contribution of AE-COPD treatment to antimicrobial resistance.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes: